Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,230.12
(
0.29%
)
US TECH 100
26,920.40
(
0.79%
)
Dow Jones
49,499.27
(
-0.31%
)
Brent Oil
107.80
(
-2.31%
)
Bitcoin
78,005.71
(
2.20%
)
News Focus
News Focus
Post# of 257482
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122925
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 225827

Wednesday, 09/25/2019 4:15:48 PM

Wednesday, September 25, 2019 4:15:48 PM

Post# of 257482
ENTA reports phase-2a NASH data for EDP-305—primary/secondary endpoints met in high-dose arm:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151356515

The rate of pruritis— 51% in the high-dose arm (with a 21% discontinuation rate due to this AE)—could be a concern.

CC at 4:30pm ET.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Unleash the power of Level 2

Spot liquidity moves with access to US order books.

Sign Up